Entrada Therapeutics (TRDA) Income from Continuing Operations (2020 - 2026)
Entrada Therapeutics (TRDA) posted Income from Continuing Operations of -$42.76 million for Q2 2026, compared with -$43.1 million a year earlier.
Powered by 
Analysis
Entrada Therapeutics (TRDA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Income from Continuing Operations at Entrada Therapeutics was -$165.82 million; for FY2025, it came in at -$143.75 million.
- In prior years, Entrada Therapeutics' Income from Continuing Operations was $65.6 million in FY2024, -$6.64 million in FY2023, -$94.62 million in FY2022 and -$51.16 million in FY2021.
- Quarterly Income from Continuing Operations has run from a low of -$44.18 million in Q3 2025 to a high of $54.99 million in Q2 2024 over five years.
- According to Business Quant data, Income from Continuing Operations for the three prior quarters was -$39.72 million (Q1 2026), -$39.16 million (Q4 2025) and -$44.18 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 3.62 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | -246.00 Mn |
| 10 | Entrada Therapeutics | 195.28 Mn | -164.13 Mn | - | -42.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.76 Mn |
| Mar 31, 2026 | -39.72 Mn |
| Dec 31, 2025 | -39.16 Mn |
| Sep 30, 2025 | -44.18 Mn |
| Jun 30, 2025 | -43.10 Mn |
| Mar 31, 2025 | -17.35 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | -13.99 Mn |
| Jun 30, 2024 | 54.99 Mn |
| Mar 31, 2024 | 23.50 Mn |
| Dec 31, 2023 | -9.50 Mn |
| Sep 30, 2023 | 35.46 Mn |
| Jun 30, 2023 | -25.93 Mn |
| Mar 31, 2023 | -6.72 Mn |
| Dec 31, 2022 | -24.63 Mn |
| Sep 30, 2022 | -25.14 Mn |
| Jun 30, 2022 | -23.18 Mn |
| Mar 31, 2022 | -21.67 Mn |
| Dec 31, 2021 | -18.45 Mn |
| Sep 30, 2021 | -14.43 Mn |
API Access
Entrada Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=TRDA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "TRDA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=TRDA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();